1. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India
- Author
-
Dawesh Prakash Yadav, Vinod K. Yadav, Sudhir K. Singh, Shivam Sachan, Anurag Tiwari, Vinod Kumar Dixit, Gaurav Garg, and Sunit Kumar Shukla
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,Sofosbuvir ,business.industry ,medicine.disease ,Gastroenterology ,Group A ,Group B ,03 medical and health sciences ,Liver disease ,Regimen ,0302 clinical medicine ,Internal medicine ,medicine ,Clinical endpoint ,030211 gastroenterology & hepatology ,Original Article ,030212 general & internal medicine ,Adverse effect ,business ,medicine.drug - Abstract
BACKGROUND/AIMS: Treatment of chronic hepatitis C infection with direct-acting antiviral (DAA) drugs has been highly effective, but data regarding benefit in advanced liver disease is relatively scarce in Indian patients. The aim of this study was to determine the effects of DAA in patients with HCV related cirrhosis (compensated/decompensated) who achieved sustained virological response post-therapy at 12 weeks (SVR12). METHODS: Sixty-three patients with HCV related cirrhosis treated with sofosbuvir based regimen were evaluated. Data regarding baseline demographics, the severity of liver disease and treatment regimen were collected. The primary end point was to evaluate the effect of treatment (SVR12) on the severity of liver disease with the secondary end point being to observe for any adverse events related to treatment. RESULTS: Treatment naïve patients with HCV cirrhosis either due to genotype 1 or genotype 3 were divided into two groups: group A (compensated cirrhosis), group B (decompensated cirrhosis). SVR12 in group A was 91.66% (33/37) and in group, B was 73.17% (30/41). Baseline mean liver stiffness measurement (LSM) in group A was 16.81 ± 3.57 kPa which decreased to 11.19 ± 1.75 kPa at SVR12 (P-value
- Published
- 2017